CEL-SCI’s Multikine® Receives Saudi FDA NADR Designation, Accelerating Potential Commercial Launch

On November 20, 2026 CEL-SCI Corporation (NYSE American: CVM) reported that its investigational cancer immunotherapy Multikine (Leukocyte Interleukin, Injection) has been granted official designation under the Saudi Food and Drug Authority’s (SFDA) New Accelerator Program for Drugs in Rare Diseases (NADR). The designation application was successfully submitted by Amarox , CEL-SCI’s in-country regulatory and commercialization partner in Saudi Arabia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The NADR designation positions Saudi Arabia to potentially become the first commercial market globally for Multikine. With NADR status secured, CEL-SCI and Amarox are preparing to submit a Marketing Authorization Application (MAA) to the SFDA within the next 2-3 months. Under recently enacted SFDA guidance, products designated under the NADR pathway qualify for priority review with a target assessment timeframe of 160 working days, supporting a potential commercial launch and initial commercial sales of Multikine in 2027 or early 2028, pending SFDA approval and review of the MAA.

"The Saudi FDA has demonstrated extraordinary global regulatory leadership by establishing the NADR program," stated Geert Kersten, Chief Executive Officer of CEL-SCI. "Their forward-looking framework perfectly aligns with Saudi Vision 2030’s mandate to bring cutting-edge healthcare innovations to the Kingdom rapidly. Because of the SFDA’s proactive approach, we are prioritizing Saudi Arabia as the potential first global commercial market for Multikine. Supported by Amarox’s deep in-country capabilities, we are not only advancing our commercialization strategy but also supporting the Kingdom’s goal of building robust, localized biopharmaceutical infrastructure. This partnership de-risks our commercial transition while delivering on our shared commitment to urgently bring life-extending therapies to head and neck cancer patients. Multikine will initially be supplied from CEL-SCI’s US based manufacturing facility."

"Our partnership with CEL-SCI represents an important step in Saudi Amarox’s strategy to expand into innovative medicines, advanced therapies, and biotechnology," said Dr. Abdullah Alzomaie, Founder and Chief Executive Officer of Saudi Amarox. "We are proud of CEL-SCI’s confidence in Amarox as its regional partner, and we are pleased to see our collaboration achieve an important early milestone through the SFDA’s NADR designation for Multikine. This progress reflects the encouraging environment Saudi Arabia is creating under Vision 2030 to support medical innovation, scientific research, and the introduction of advanced therapies. We see this as the beginning of a promising and long-term partnership."

Accelerated Regulatory Pathway Aligned with Saudi Vision 2030

Launched by the SFDA in August 2026, the NADR program is a cornerstone initiative supporting the healthcare transformation goals of Saudi Vision 2030 and the Kingdom’s National Biotechnology Strategy. NADR is designed to expedite the evaluation of breakthrough therapies that address serious diseases with high unmet medical needs, ensuring Saudi citizens have first-in-class access to advanced medicines. Key benefits of the designation include:

Priority 160-Working-Day Assessment: Eligibility for accelerated review under SFDA submission guidance effective January 1, 2027, establishing a clear pathway for a potential 2027 or early 2028 Multikine launch.
Collaborative Regulatory Framework: Dedicated access to scientific advice and tailored evaluation frameworks, reflecting the SFDA’s commitment to agile, science-based regulation.
Streamlined Access Pathways: Accelerated frameworks designed to bring high-impact immunotherapies to patients rapidly.
Capital-Efficient Commercialization & Local Capability Building

Under the terms of the strategic partnership announced in May 2026, Amarox is CEL-SCI’s local regulatory representative and exclusive commercial distributor for Multikine in Saudi Arabia. Beyond establishing a capital-efficient, 50% / 50% net revenue-sharing model for CEL-SCI, the partnership directly supports Saudi Arabia’s localization goals by utilizing fully funded, in-country marketing, logistics, and sales infrastructure. The agreement also includes an option to expand this localized commercial framework into the broader Gulf Cooperation Council (GCC) member states—including the United Arab Emirates, Kuwait, Qatar, Bahrain, and Oman.

Compelling Phase 3 Clinical Foundation

CEL-SCI intends to seek marketing authorization in Saudi Arabia for the exact target population defined in its planned U.S. registration study: newly diagnosed, previously untreated adult patients with locally advanced, resectable oral cavity squamous cell carcinoma with no lymph node involvement and low/zero tumor PD-L1 expression.

In the world’s largest Phase 3 study for locally advanced head and neck cancer, neoadjuvant treatment with Multikine before standard of care (SOC) delivered dramatic survival benefits in this target population:

73% 5-Year Overall Survival vs. 45% for SOC alone (p = 0.0015).
66% Relative Reduction in Risk of Death compared to SOC alone (Hazard Ratio = 0.34).
Strong Neoadjuvant Mechanism: Administered locally over three weeks immediately following diagnosis, activating an intact immune system prior to surgery, radiation, and chemotherapy.
First Berlin, based in Berlin, Germany, which facilitated the partnership, continues to support CEL-SCI and Amarox as the program moves towards submission and launch in the Kingdom.

About Multikine

Multikine is a novel cancer immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated locally advanced head and neck cancer. It is manufactured at scale, stored in a vial, and injected directly around the tumor. Its goal is to activate a person’s immune system to fight cancer before the ravages of surgery, radiation and chemotherapy have weakened the immune system. In the world’s largest locally advanced head and neck cancer Phase 3 study, Multikine increased the 5-year survival rate of the target patient population to 73% vs 45% in patients treated with standard of care alone and halved the risk of death from 55% to 27%.

(Press release, Cel-Sci, NOV 20, 2026, https://feeds.issuerdirect.com/news-release.html?newsid=7639396368792088&symbol=CVM [SID1234675034])